Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adhiron αC-8
- Development stage
- Preclinical
- Lead developer
- University of Leeds
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Intravenous
01
Overview
Adhiron αC-8 is a preclinical-stage small conformational protein binder (12 kDa) based on a plant cystatin scaffold [OC 09.3]. Developed by researchers at the University of Leeds, it is designed to target the intrinsically disordered fibrinogen αC-region with high affinity and specificity [OC 09.3]. By binding to the fibrinogen αC-region, Adhiron αC-8 modulates fibrin clot structure, reduces clot stiffness, enhances whole blood clot contraction (producing smaller clots), and reduces thrombus size in vivo without affecting bleeding time [OC 09.3]. It is being investigated for its potential to regulate haemostatic imbalance and protect against venous thromboembolism [OC 09.3].
- Other names
- Adhiron alphaC-8
02
Targets
FGA (Fibrinogen alpha chain)
Beyond the preview
Go deeper on Adhiron αC-8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adhiron αC-8.